Search
  • HPR

MRI on-line Spring 2020


Press release


“HPR, a preclinical CRO specializing in pharmacological evaluation of novel therapeutics in nonhuman primate disease models, is scheduled to operate its own 1.5T GE Healthcare MRI by March 2021.

The MRI would be completely managed and operated by HPR, thereby increasing access to in vivo imaging for HPR studies.”

“CEO Dr. Hiroyuki Takamatsu notes, “In vivo imaging has become a significant component of our contract studies and we are committed to meeting the needs of future clients. To address future needs, we will be making a significant commitment to our infrastructure by doubling MRI capacity, in terms of both staffing and equipment. We highly appreciate the support of our past and current clients.“

7 views

Recent Posts

See All

Follow us:

HPR's AAALAC
HPR ProudCROMember_Biocom

Copyright © HAMAMATSU PHARMA RESEARCH U.S.A., Inc All rights reserved.

Hamamatsu Pharma Research U.S.A., Inc

3070 Bristol Street, Suite 400 Costa Mesa, CA 92626

E-mail: info_us[at]hpharma.jp